Diquafosol
As of the edition of 20 October 2026, Diquafosol is a small molecule: marketed, first approved in 2010 (JP); acts on P2RY1, P2RY2 and P2RY4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- First approved
- 9 February 2010 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Santen Pharmaceutical
- Registered trials
- 28, 1 stopped early
- Disease areas
- Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Diquafosol.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 5 | 2 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 5 | 3 | 0 | 1 |
| Phase 3 | 7 | 7 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Santen Pharmaceutical | Originator and Lead sponsor of trials | 2010 to now |